Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Investigating a viral mechanism targeting eIF4E phosphorylation in cancer

FY 2013-14

Summary
Cancer remains the most devastating disease facing the health of Canadians, with an estimated 500 patients succumbing to malignancies every day. Unfortunately, the current repertoire of clinically effective drugs that combat cancer progression is lacking, and extensive efforts are focused on the development of targeted therapies that affect known drivers of oncogenesis. The unifying characteristic of all cancers studied to date is the emergence of cells that grow and divide at an uncontrollable rate. To sustain rapid growth and proliferation, cancer cells must generate abnormally high levels of proteins that favour these properties. Thus, the control of protein synthesis is frequently dysregulated in cancer. We and others have identified the eukaryotic translation initiation factor 4E (eIF4E) as a contributor to cancer etiology, which promotes aberrant protein production. My studies will focus on a form of eIF4E that is modified by a process called phosphorylation. Normally, signals that tell the cell to grow and proliferate induce the phosphorylation of eIF4E by proteins called Mnk1 and Mnk2. However, in many cancers phosphorylated eIF4E levels are much higher than normal due to overactivation of Mnk1 and Mnk2, which contributes to tumor growth and metastasis. Intriguingly, a class of pathogens called adenoviruses have evolved a method of specifically preventing Mnk1 and Mnk2 from phosphorylating eIF4E, by expression of a viral protein called L4-100kDa (L4A). Our research will use structural biology to determine, at an atomic level, precisely how L4A prevents eIF4E phosphorylation. Using cellular and mouse models of breast cancer, we then intend to test whether a peptide therapy based on L4A can be an effective approach in the treatment of cancer. This innovative strategy will exploit an evolutionarily conserved mechanism of inhibiting eIF4E phosphorylation, in the hopes of designing novel drug compounds that benefit Canadians in the ongoing fight against cancer.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
307750
Name
Rouya Christopher M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating a viral mechanism targeting eIF4E phosphorylation in cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Eif4e Phosphorylation; Mechanisms Of Viral Translational Inhibition; Mrna Translation; Peptide Therapy; Structure-Based Drug Design; X-Ray Crystallography
Abstract
Cancer remains the most devastating disease facing the health of Canadians, with an estimated 500 patients succumbing to malignancies every day. Unfortunately, the current repertoire of clinically effective drugs that combat cancer progression is lacking, and extensive efforts are focused on the development of targeted therapies that affect known drivers of oncogenesis. The unifying characteristic of all cancers studied to date is the emergence of cells that grow and divide at an uncontrollable rate. To sustain rapid growth and proliferation, cancer cells must generate abnormally high levels of proteins that favour these properties. Thus, the control of protein synthesis is frequently dysregulated in cancer. We and others have identified the eukaryotic translation initiation factor 4E (eIF4E) as a contributor to cancer etiology, which promotes aberrant protein production. My studies will focus on a form of eIF4E that is modified by a process called phosphorylation. Normally, signals that tell the cell to grow and proliferate induce the phosphorylation of eIF4E by proteins called Mnk1 and Mnk2. However, in many cancers phosphorylated eIF4E levels are much higher than normal due to overactivation of Mnk1 and Mnk2, which contributes to tumor growth and metastasis. Intriguingly, a class of pathogens called adenoviruses have evolved a method of specifically preventing Mnk1 and Mnk2 from phosphorylating eIF4E, by expression of a viral protein called L4-100kDa (L4A). Our research will use structural biology to determine, at an atomic level, precisely how L4A prevents eIF4E phosphorylation. Using cellular and mouse models of breast cancer, we then intend to test whether a peptide therapy based on L4A can be an effective approach in the treatment of cancer. This innovative strategy will exploit an evolutionarily conserved mechanism of inhibiting eIF4E phosphorylation, in the hopes of designing novel drug compounds that benefit Canadians in the ongoing fight against cancer.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rouya, Christopher M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2013-14) | Canada Spends